This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lo, J. C. Articles by Schambelan, M. Search for Related Content PubMed PubMed Citation Articles by Lo, J. C. Articles by Schambelan, M.

The Effects of Recombinant Human Growth Hormone on Body Composition and Glucose Metabolism in HIV-Infected Patients with Fat Accumulation

Division of Endocrinology, Department of Medicine (J.C.L., K.M., M.A.N., J.-M.S., C.G., M.S.), and Department of Radiology (R.A.H), University of California–San Francisco, San Francisco, California 94143; and Department of Nutritional Sciences (J.-M.S.), University of California–Berkeley, Berkeley, California 94720

Address all correspondence and requests for reprints to: Joan C. Lo, M.D., Division of Endocrinology, San Francisco General Hospital, Building 30, Room 3501-K, San Francisco, California 94110. E-mail: jlo{at}itsa ucsf.edu.

Abstract

GH has been proposed as a therapy for patients with HIV-associated fat accumulation, but the pharmacological doses (6 mg/d) used have been associated with impaired fasting glucose and hyperglycemia. In contrast, physiologic doses of GH ( 1 mg/d) in HIV-negative men reduced visceral adiposity and eventually improved insulin sensitivity, despite initially causing insulin resistance. We conducted an open-label study to evaluate the effects of a lower pharmacologic dose of GH (3 mg/d) in eight men with HIV-associated fat accumulation. Oral glucose tolerance, insulin sensitivity, and body composition were measured at baseline, and 1 and 6 months. Six patients completed 1 month and 5, 6 months of GH therapy. IGF-I levels increased 4-fold within 1 month of GH treatment. Over 6 months, GH reduced buffalo hump size and excess visceral adipose tissue. Total body fat decreased (17.9 ± 10.9 to 13.5 ± 8.4 kg, P = 0.05), primarily in the trunk region. Lean body mass increased (62.9 ± 6.4 to 68.3 ± 9.1 kg, P = 0.03). Insulin-mediated glucose disposal, measured by a euglycemic hyperinsulinemic clamp, declined at month 1 (49.7 ± 27.5 to 25.6 ± 6.6 nmol/kg_LBM·min/pmol_INSULIN/liter, P = 0.04); values improved at month 6 (49.2 ± 22.6, P = 0.03, compared with month 1) and did not differ significantly from baseline. Similarly, the integrated response to an oral glucose load worsened at month 1 (glucose area under the curve 20.1 ± 2.3 to 24.6 ± 3.7 mmol·h/liter, P < 0.01), whereas values improved at month 6 (22.1 ± 1.5, P = 0.02, compared with month 1) and did not differ significantly from baseline. One patient developed symptomatic hyperglycemia within 2 wk of GH initiation; baseline oral glucose tolerance testing revealed preexisting diabetes despite normal fasting glucose. In conclusion, GH at 3 mg/d resulted in a decrease in total body fat and an increase in lean body mass in this open-label trial. While insulin sensitivity and glucose tolerance initially worsened, they subsequently improved toward baseline. However, the dose of GH used in this trial was supraphysiologic and led to an increase in IGF-I levels up to three times the upper normal range. Because there are known adverse effects of long-term GH excess, the effectiveness of lower doses of GH should be studied. We also recommend a screening oral glucose tolerance test be performed to exclude subjects at risk for GH-induced hyperglycemia.

This article has been cited by other articles:

				K. Mulligan, H. Khatami, J.-M. Schwarz, G. K. Sakkas, A. M. DePaoli, V. W. Tai, M. J. Wen, G. A. Lee, C. Grunfeld, and M. Schambelan The Effects of Recombinant Human Leptin on Visceral Fat, Dyslipidemia, and Insulin Resistance in Patients with Human Immunodeficiency Virus-Associated Lipoatrophy and Hypoleptinemia J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1137 - 1144. [Abstract] [Full Text] [PDF]

				J. E. Mallewa, E. Wilkins, J. Vilar, M. Mallewa, D. Doran, D. Back, and M. Pirmohamed HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options J. Antimicrob. Chemother., October 1, 2008; 62(4): 648 - 660. [Abstract] [Full Text] [PDF]

				J. Lo, S. M. You, B. Canavan, J. Liebau, G. Beltrani, P. Koutkia, L. Hemphill, H. Lee, and S. Grinspoon Low-Dose Physiological Growth Hormone in Patients With HIV and Abdominal Fat Accumulation: A Randomized Controlled Trial JAMA, August 6, 2008; 300(5): 509 - 519. [Abstract] [Full Text] [PDF]

				T. T. Brown Approach to the Human Immunodeficiency Virus-Infected Patient with Lipodystrophy J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2937 - 2945. [Abstract] [Full Text] [PDF]

				J. G. Esposito, S. G. Thomas, L. Kingdon, and S. Ezzat Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting Am J Physiol Endocrinol Metab, September 1, 2005; 289(3): E494 - E503. [Abstract] [Full Text] [PDF]

				A Munafo, T X Q Nguyen, O Papasouliotis, H Lecuelle, A Priestley, and M O Thorner Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects Eur. J. Endocrinol., August 1, 2005; 153(2): 249 - 256. [Abstract] [Full Text] [PDF]

				A. Milinkovic and E. Martinez Current perspectives on HIV-associated lipodystrophy syndrome J. Antimicrob. Chemother., July 1, 2005; 56(1): 6 - 9. [Abstract] [Full Text] [PDF]

				A. Vigano, S. Mora, P. Manzoni, L. Schneider, S. Beretta, M. Molinaro, B. di Natale, and P. Brambilla Effects of Recombinant Growth Hormone on Visceral Fat Accumulation: Pilot Study in Human Immunodeficiency Virus-Infected Adolescents J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4075 - 4080. [Abstract] [Full Text] [PDF]

				P. Koutkia, B. Canavan, J. Breu, and S. Grinspoon Growth Hormone (GH) Responses to GH-Releasing Hormone-Arginine Testing in Human Immunodeficiency Virus Lipodystrophy J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 32 - 38. [Abstract] [Full Text] [PDF]

				P. Koutkia, B. Canavan, J. Breu, M. Torriani, J. Kissko, and S. Grinspoon Growth Hormone-Releasing Hormone in HIV-Infected Men With Lipodystrophy: A Randomized Controlled Trial JAMA, July 14, 2004; 292(2): 210 - 218. [Abstract] [Full Text] [PDF]

				S. Benavides and M. C Nahata Pharmacologic Therapy for HIV-Associated Lipodystrophy Ann. Pharmacother., March 1, 2004; 38(3): 448 - 457. [Abstract] [Full Text] [PDF]

				T.-J. Wu, S.-M. Huang, R. L. Taylor, and P. C. Kao Thyroxine Effects on Serum Insulin-like Growth Factor I Levels, Anthropometric Measures, and Body Composition in Patients After Thyroidectomy Ann. Clin. Lab. Sci., October 1, 2003; 33(4): 423 - 428. [Abstract] [Full Text] [PDF]

				Q. He, E. S. Engelson, J. B. Albu, S. B. Heymsfield, and D. P. Kotler Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy J Appl Physiol, May 1, 2003; 94(5): 2051 - 2057. [Abstract] [Full Text] [PDF]

				M. K. S. Leow, C. L. Addy, and C. S. Mantzoros Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic Strategies J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1961 - 1976. [Full Text] [PDF]

				M J Rennie Claims for the anabolic effects of growth hormone: a case of the Emperor's new clothes? Br. J. Sports Med., April 1, 2003; 37(2): 100 - 105. [Abstract] [Full Text] [PDF]

				D. Chen, A. Misra, and A. Garg Lipodystrophy in Human Immunodeficiency Virus-Infected Patients J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4845 - 4856. [Abstract] [Full Text] [PDF]

				S. Grinspoon and M. Gelato Editorial: The Rational Use of Growth Hormone in HIV-Infected Patients J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3478 - 3479. [Full Text] [PDF]